$CELZ. NEWS imminent 3.27.18 Four From D's fi
Post# of 103015
(Total Views: 287)
Posted On: 03/29/2018 1:36:27 PM
$CELZ. NEWS imminent
3.27.18 Four From D's filed !
3.27.18 As our 10K is being finalized for filing this week
December 18'
Urologist to the Stars” Dr. Alexander Gershman Begins Treating Patients with Patented Caverstem TM
Stem Cell Procedure for Drug Refractory Erectile Dysfunction
8K
December 18, 2017
Phoenix, AZ/Los Angeles, CA) Creative Medical Technology Holdings Inc. (OTCQB ticker symbol CELZ) announced today initiation of patient treatments using its patented Caverstem™ procedure by Dr. Alexander Gershman.
Dr. Alexander Gershman, Director of The Institute of Advanced Urology at the Cedars-Sinai Medical Tower; Director of Urologic Laparoscopy in the Division of Urology, Harbor-UCLA Medical Center, began treating patients with the procedure, which involves extraction of a small amount of bone marrow, concentration of bone marrow derived stem cells, and subsequent administration to the patient within less than 30 minutes.
“There is much excitement about stem cells revolutionizing many aspects of medicine. I am enthusiastic to be offering this cutting edge procedure to my patients, for which previous therapies have failed or are too invasive.” Said Dr. Gershman. “Numerous publications and a recent clinical trial at the Los Angeles Biomedical Institute at Harbor – UCLA Hospital in Torrance, CA, support the safety and feasibility of the Caverstem™ procedure. The biological basis of the bone marrow based treatment is that in patients with drug non-responsive erectile dysfunction, there is a deficit in function of smooth muscle and blood vessel cells. By administering the patient’s own stem cells we aim to rebuild these damaged tissues, and thereby restore erectile function.”
Creative Medical Health Technology Holdings is offering the Caverstem™ procedure to selected urologists in the USA, which qualify according to the Company’s criteria. Approximately 30% of the 30,000,000 patients suffering from erectile dysfunction do not respond to drugs like Viagra, Cialis and Levitra, in part due to an underlying degeneration of the biological machinery needed to achieve erections.
“We are pleased to have received such enthusiasm from one of the Opinion Leaders of the Urology community in the first 30 days of commercialization and anticipate similar responses as we expand our physician base throughout the United States” said Timothy Warbington, President and CEO of Creative Medical Technology Holdings Inc.
https://backend.otcmarkets.com/otcapi/company...ntent/html
Aloha
3.27.18 Four From D's filed !
3.27.18 As our 10K is being finalized for filing this week
December 18'
Urologist to the Stars” Dr. Alexander Gershman Begins Treating Patients with Patented Caverstem TM
Stem Cell Procedure for Drug Refractory Erectile Dysfunction
8K
December 18, 2017
Phoenix, AZ/Los Angeles, CA) Creative Medical Technology Holdings Inc. (OTCQB ticker symbol CELZ) announced today initiation of patient treatments using its patented Caverstem™ procedure by Dr. Alexander Gershman.
Dr. Alexander Gershman, Director of The Institute of Advanced Urology at the Cedars-Sinai Medical Tower; Director of Urologic Laparoscopy in the Division of Urology, Harbor-UCLA Medical Center, began treating patients with the procedure, which involves extraction of a small amount of bone marrow, concentration of bone marrow derived stem cells, and subsequent administration to the patient within less than 30 minutes.
“There is much excitement about stem cells revolutionizing many aspects of medicine. I am enthusiastic to be offering this cutting edge procedure to my patients, for which previous therapies have failed or are too invasive.” Said Dr. Gershman. “Numerous publications and a recent clinical trial at the Los Angeles Biomedical Institute at Harbor – UCLA Hospital in Torrance, CA, support the safety and feasibility of the Caverstem™ procedure. The biological basis of the bone marrow based treatment is that in patients with drug non-responsive erectile dysfunction, there is a deficit in function of smooth muscle and blood vessel cells. By administering the patient’s own stem cells we aim to rebuild these damaged tissues, and thereby restore erectile function.”
Creative Medical Health Technology Holdings is offering the Caverstem™ procedure to selected urologists in the USA, which qualify according to the Company’s criteria. Approximately 30% of the 30,000,000 patients suffering from erectile dysfunction do not respond to drugs like Viagra, Cialis and Levitra, in part due to an underlying degeneration of the biological machinery needed to achieve erections.
“We are pleased to have received such enthusiasm from one of the Opinion Leaders of the Urology community in the first 30 days of commercialization and anticipate similar responses as we expand our physician base throughout the United States” said Timothy Warbington, President and CEO of Creative Medical Technology Holdings Inc.
https://backend.otcmarkets.com/otcapi/company...ntent/html
Aloha
(2)
(0)Scroll down for more posts ▼